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Abstract
Background: Systemic  lupus  erythematosus (SLE) may be characterized by periods of  remissions and chronic or acute 
relapses. The complexity of  clinical presentation of  the SLE patients leads to incorrect evaluation of  disease activity. Mean 
platelet volume (MPV) has been studied as a simple inflammatory  marker in several diseases. There is no study in the litera-
ture about MPV levels in adult SLE patients with arthritis.
Objectives: We aimed to investigate  the  MPV  levels  in  the SLE  population  with  arthritis  during  and  between activa-
tions.
Methods: The study consisted of  44 SLE patients with arthritis in activation period (Group 1), the same 44 SLE patients 
with arthritis in remission period (Group 2) and 44 healthy controls (Group 3). Erythrocyte sedimentation rate (ESR), c-
reactive protein (CRP), white blood cell count, platelet count, and mean platelet volume (MPV) levels were retrospectively 
recorded from patient files.
Results: The mean ages of  the SLE subjects were 42 ± 16 years, while the mean ages of  controls was 41 ± 17 years. MPV 
was significantly lower in Group 1(7.66±0.89fL) than in Group 2 (8.61±1.06 fL) and Group 3(8.62±1.11fL) (p<0.0001). The 
differences between groups reached statistical significance.
Conclusions: We suggest that MPV levels decrease in patients with arthritis of  SLE activation when compared to the same 
patients in remission and healthy controls.
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Introduction
Systemic lupus erythematosus  (SLE) is a chronic in-
flammatory  disease of  unknown cause that may affect 
any organ of  the body. Arthritis lupus is typically non-
erosive,  non-deforming,  and frequently appears before 
other manifestations  of  SLE. It affects predominant-
ly women, especially in their 20s and 30s. The clinical 
course of  SLE is characterized by periods of  remissions 
and relapses1. The correct evaluation of  disease activity 
is of  great importance  because of  the the complexity 
of  the disease.  Common  methods  including  erythro-
cyte sedimentation  rate  (ESR)  and  C-reactive  protein 
(CRP)  are  not  completely  in  accordance  with  eval-
uating activation of  SLE with arthritis2,3. Anti-double 
stranded DNA antibody and complement are used to 
certain clinical  manifestations  of  the  disease,  espe-
cially  nephritis,  rather  than the  activity  of  the  disease 
itself    and arthritis4. Currently, disease activity in SLE 
can be assessed using composite disease activity indi-
ces, such as the SLE Disease Activity Index (SLEDAI) 
and British Isles Lupus Assessment  Group (BILAG) 
5. However, they could be complex for use in routine 
clinical practice. Therefore, there is a great amount of  
interest in the identification of  biomarkers that can 
quantify disease activity, although a single biomarker 
is unlikely to replace clinical evaluation because of  the 
heterogeneity of  SLE6.
Mean platelet volume (MPV) is a parameter detected 
during routine blood count and to which clinicians 
do not usually pay much attention. Platelet volume is 
known to be a marker determined  from megakaryo-
cytes during   platelet   production,   which   is   associ-
ated   with   platelet   function   and   activation.   Under 
normal circumstances,  there is an inverse relationship 
between platelet size and number7,8. MPV has been 
studied as a simple inflammatory marker in several dis-
eases. Some studies have reported that MPV increases 
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in myocardial infarction and cerebrovascular  disease; 
while in contrast, it decreases in active rheumatologic 
diseases including rheumatoid arthritis (RA), ankylosing 
spondylitis and ulcerative colitis9-12. To our knowledge, 
there is not a study  in  the  literature  about  MPV  lev-
els  in  adult  SLE  patients  with  arthritis.  The  present 




The data used in the present  study were obtained  retro-
spectively  from patients  who had SLE diagnosis  with 
arthritis complaints based on ACR criteria in August 
2011-December 2012 period in Rheumatology Clinic 
of  the School of  Medicine of  the Cumhuriyet Univer-
sity (Sivas, Turkey). Ethical approval for the study was 
obtained from  the  local  ethics  committee.  The study 
consisted of  44 SLE patients with arthritis in activation 
period (Group 1), the same 44 SLE patients with arthri-
tis in remission period (Group 2) and 44 healthy con-
trols (Group 3).  The age of  SLE patients and healthy 
controls ranged in 18 to 79 years. Participants with a 
history of  smoking, acute or chronic infectious diseas-
es, hemoglobin >16.5 g/dl, thrombocytopenia, anemia, 
hypertension, angina pectoris, myocardial infarction, di-
abetes mellitus, anti-phospholipid syndromes, recurrent 
miscarriage, amyloidosis, thrombosis or chronic renal 
insufficiency were excluded from the study. ESR, CRP, 
White Blood Cell (WBC) count, platelet count, and 
MPV levels were retrospectively  recorded from patient 
files. All blood samples  were  studied  within  less  than 
one  hour  after  the  sampling.  The  complete  blood 
count  have  been performed  in the  same  analyzer, 
Mindray  BC-6800,  which  is routinely  checked  every 
month  in the  central laboratory of  our institution.
Statistical analyses
Data were evaluated using the Statistical Package for 
Social Sciences 12.0 program for windows and by 
analyzing descriptive statistics (means and standard 
deviation), comparing the means of  quantitative data 
for more than two groups with Kruskal–Wallis test and 
by comparing dual groups using the Student’s t-test. P 
value of   0.05  was  considered   significant.   Correla-
tions   between   parameters   were  computed   through 
Pearson’s correlation  analysis.  Variables  found  to  be 
statistically  significant  in  univariate  analyses  were 
entered  into multivariate   logistic  regression   analysis. 
Multivariate   logistic  regression   models  were  created 
to  identify independent predictors of  activation of  
arthritis in SLE patients. 
 
Results
Demographic  and clinical  features  of  SLE patients 
are given in Table I. 
The mean ages of  the SLE subjects were 42 ± 16 years, 
while the mean ages of  controls  was 41 ± 17 years. 
Thirty-three SLE patients (78.6%) and 35 subjects 
(79.5%) in control group were female. There were no 
significant differences between patient group with SLE 
and healthy controls in terms of  age and gender distri-
bution (p=0.628, p=0.912,  respectively).
MPV was significantly  lower in Group 1 (7.66±0.89fL) 
than in Grouand Group 3(8.62±1.11fL)  (p<0.0001); 
however,  there  was no difference  between group  2 
and group  3 (p=0.772).  MPV levels were not corre-
lated with ESR and CRP.    
Table I. Main clinical characteristics of  the patients with systemic lupus erythematosus and of  the controls*






































































































The mean platelet volume and WBC count did not differ 
among the groups.  CRP  and ESR values  were  signifi-
cantly  higher  in Group  1 than Group  2 (p<0.0001). 
All study parameters  are presented  in Table  II and III. 
Table III. Relationship between blood parameters in Group 1 and Group 3 






Sex, no. female/male 33/11 35/9 
Median age, years (range) 42±16 41 ±17 
Age at SLE onset, years(range) 32±8.9 - 
Remission duration, days (range) 12±4.9 - 
Butterfly rash 28/44 - 
Discoid lesions 11/44 - 
Photosensitivity 23/44 - 
Mouth ulcers 14/44 - 
Arthralgias/arthritis 44/44 - 
Serositis 4/44 - 
Pleurisy 4/44 - 
Pericarditis 1/44 - 
Renal disease 12/44 - 
Neuropsychiatric manifestations 4/44 - 
Antinuclear antibodies 41/44 - 
Anti–double-stranded  DNA 24/44 - 
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Correlation analysis showed that there was positive cor-
relation between CRP (r= 0.534, p=0.001) and ESR (r= 
0.556, p=0.001) and negative correlation between MPV 
(r=-0.445, p=0.001) in activation period SLE patients 
with arthritis (Figure I). 
Figure I: Roc-curve analysis of  MPV
ESR, CRP, MPV, platelet count, and WBC were entered 
in univariate analysis. CRP, ESR, and MPV were statisti-
cally important. These values were entered  multivariate 
analyses  to  identify  independent  predictors  of   acti-
vation  of   arthritis  in  SLE  patients.
Multivariate  analysis  showed  that only MPV (odds 
ratio:  0,179, %CI: 0.048-0.671,  p=0.011)  and ESR 
(odds ratio:  1.134,  %CI:  1.040-1.235,  p=0.004)  were 
independent  predictors  of  arthritis  activation  in SLE 
patients (Table  IV).
Table IV. Univariate and multivariate analyses
MPV: Mean platelet volume, WBC: White blood cell, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate
Discussion
In the present study, we demonstrated that MPV de-
creased in SLE patients during activation compared 
with remission and healthy controls. Low levels of  
MPV were associated with disease activity. We suggest 
its usefulness as a biomarker  for global disease activ-
ity and clinical features. In patients with SLE, elevated 
ESR were found to be associated with disease activity 13, 
whereas serum CRP was only slightly elevated and was 
not correlated with disease activity3, 14. However, CRP 
and ESR may present some discordance in reflecting 
inflammation4. Recently,  MPV has been considered  a 
reliable  marker  for indicating  platelet  activation  and 
inflammation.  MPV  is  easily  measured  by  automated 
cell  counters  under  any  storage  conditions  for  blood 
samples. MPV is a marker of  platelet function and acti-
vation, and it is also influenced by inflammation15.
To our knowledge, there is only one study in the lit-
erature about MPV levels in adult SLE patients. In this 
study, low MPV (<7.2 fl) was recorded by 2 different 
hematology analyzers in 5 (14.3%) and 23 (65.7%) pa-
tients  with  SLE,  mostly  at  active  stage  of  the  dis-
ease  (n=28,  80%).16  Results  of  this study,  in which 
hematological parameters of  SLE patients were studied, 
were in accordance with our results. A major difference 
of  the present study from the ones in literature was that 
this is the first study evaluating  MPV in SLE patients 
with arthritis in activation and remission periods.
Gasparyan et al.15 stated that high-grade inflammation 
accompanies  a decrease of  MPV in RA and SLE,  pos-
sibly due to the  increased consumption of  large plate-
lets at the sites of  rheumatoid  inflammation.
Kisacik  et al.7 found  that  MPV was  low  in active  an-
kylosing  spondylitis  and  RA,  and  that  MPV  levels 
increased and then normalized with treatment.   In an-
other study lower MPV value of  RA patients compared 
to controls  were shown to increase  after TNF-α treat-
ment17. In the present study, lower MPV values of  SLE 
patients with arthritis were normalized after treatment. 
There are two studies showing that MPV levels of  FMF 
patients during the attack were significantly lower than 
those of  healthy controls18,19. MPV has been reported 
to decrease in some inflammatory bowel diseases such 
as ulcerative colitis and it could be used for determina-
tion of  disease  activity20. This condition  is thought to 
be related  to the release  of  bioactive  molecules of  
pro-inflammatory platelets in the presence of  inflam-
mation.
Two studies have suggested that SLE patients have in-
creased platelet activation21, 22. Of  these studies, Naga-
hama et al.22 showed that plasma platelet-derived micro-
particle levels were significantly higher in SLE patients 
than in healthy subjects. Furthermore, Nagahama et 
al stated22 that MPV levels were decreased in patients 
with arthritis of  SLE activation as in our study. Several 
mechanisms for how complement components interact 
with platelets have been proposed, and most of  these 
theories involve platelet activation.
Common trigger of  platelets include immune com-
plexes, which are frequently seen in SLE patients, shear 
stress due to atherosclerosis or inflammatory cytokines 
including interferon-alpha21, 23, 24.
Limitations
The results of  this study are subjected to some limita-
tions.  First, this study was not based on longitudinal 
observations but was conducted with a retrospective 
design. Second, since the study is retrospective, clinical 
activation indices of  SLE patients with arthritis (SLE-
DAI, BILAG) were not calculated. Third, it is a single 
center study with a relatively small sample size, which 
might underestimate  or overestimate  the relationship 
between MPV and inflammation in SLE patients pre-
sented with arthritis. Fourth, the fact that MPV values 
may be affected by many factors.
Conclusion  
we suggest that MPV levels decrease  in patients with 
arthritis of  SLE activation  when compared  to same 
patients  with  remission  and  healthy  controls.    De-
creased  MPV  levels  were  observed  in patients with 
SLE and these results may be related to active inflam-
matory  states. Namely, MPV is associated with disease 
activity.  The  results  of   our  study  further  expand 
perspectives  of   use  of   MPV  in  conditions associated 
with SLE with arthritis for monitoring treatment. So, 
more specifically designed prospective studies are need-
ed to externally cross-validate our findings in a larger 
cohort of  APS patients.
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